8-Amino-imidazo<1,2-b>pyridazin | 56477-92-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 8-Amino-imidazo<1,2-b>pyridazin
• 英文别名: imidazo[1,2-b]pyridazin-8-ylamine；Imidazo[1,2-B]pyridazin-8-amine
• CAS: 56477-92-0
• 化学式: C₆H₆N₄
• mdl: MFCD19208390
• 分子量: 134.14
• InChiKey: NAUOUPATZLZONR-UHFFFAOYSA-N

物化性质

• 熔点：
  168-171 °C(Solv: ethyl acetate (141-78-6))
• 密度：
  1.50±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-Amino-imidazo<1,2-b>pyridazin 以72%的产率得到
  参考文献：
  名称：

  POLANC S.; STAMOVNIK B.; TISLER M., SYNTHESIS , 1975, NO 3, 175-176

  摘要：

  DOI：

文献信息

• Heterocyclic kinase inhibitors
  申请人：AbbVie Inc.

  公开号：US10280184B2

  公开（公告）日：2019-05-07

  The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  本发明提供了式（I）化合物的药学上可接受的盐、原药、生物活性代谢物、立体异构体和异构体，其中变量在本文中定义。本发明的化合物可用于治疗免疫学和肿瘤学疾病。
• FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1928879B1

  公开（公告）日：2013-02-13
• HETEROCYCLIC KINASE INHIBITORS
  申请人：AbbVie Inc.

  公开号：US20170114077A1

  公开（公告）日：2017-04-27

  The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
• HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS
  申请人：eFFECTOR Therapeutics, Inc.

  公开号：US20170145009A1

  公开（公告）日：2017-05-25

  The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula IA or Formula IB, as well as stereoisomers, tautomers or pharmaceutically acceptable salts thereof. For Formula IA and Formula IB compounds A 1 , A 2 , A 3 , A 4 , W 1 , W 2 , Y, X, R 1 , R 2 , R 3 , R 4a , R 4b , R 5a , R 5b , R 6 , R 7 , R 8 , R 9 , R 9a , R 9b , R 10 and subscript n are as defined in the specification. The inventive Formula IA and Formula IB compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.